Results

AbbVie Inc.

05/23/2022 | Press release | Distributed by Public on 05/23/2022 06:06

AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting